Craig-Hallum Initiates Coverage On Galmed Pharmaceuticals with Buy Rating, Announces $18 Price Target

Craig-Hallum analyst Francois Brisebois initiates coverage on Galmed Pharmaceuticals (NASDAQ:GLMD) with a Buy rating and a $18 price target.

Benzinga · 02/04/2020 13:42

Craig-Hallum analyst Francois Brisebois initiates coverage on Galmed Pharmaceuticals (NASDAQ:GLMD) with a Buy rating and a $18 price target.